<DOC>
	<DOC>NCT01484262</DOC>
	<brief_summary>This study is conducted in Europe. The intention of this health service research study is to obtain data from daily routine to evaluate the quality of life and the costs of the disease for patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtained before any studyrelated activities. (Studyrelated activities are any procedures related to recording of data according to the protocol) Patients willing and able to give signed consent on matching patient data with sick fund data Patients diagnosed with type 2 diabetes mellitus, currently treated with oral antidiabetic medication, who need treatment intensification with insulin or liraglutide (VictozaÂ®) due to inadequate blood glucose control Patient is a member of the involved sick fund (AOK Plus) Known or suspected contraindication to the relevant study product according to current SPC Previous participation in this study History of type 1 diabetes mellitus Previous insulin treatment excluding emergency administration (treatment duration up to a maximum of 3 days) Previous treatment with liraglutide History of diabetic gastroparesis, diabetic precoma or diabetic ketoacidosis Progressive fatal disease Any reason in judgement of the treating physician that precludes study participation e.g. lack of compliance, safety concerns, alcohol or drug abuse Patients without legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>